Rheumatology

Diagnosis and Screening: Looking Beyond Density

At a Glance

Drug-induced osteoporosis cannot be assessed by bone density alone. A complete evaluation combines medication history, fracture history, DXA results, and—when indicated—VFA, TBS, adjusted FRAX, and laboratory tests to identify hidden fracture risk.

When you are taking medications that affect bone, a standard bone density test is often not enough to see the whole picture. In drug-induced osteoporosis, your bones can become “fragile” and prone to breaking even if your density numbers look relatively safe ^[1]^[2]. Diagnosis requires a more comprehensive approach that looks at clinical history and bone quality, not just bone density.

The DXA Scan: More Than Just a Number

A Dual-energy X-ray Absorptiometry (DXA) scan measures your Bone Mineral Density (BMD).

For postmenopausal women and men aged 50 or older, it compares your bones to those of a healthy young adult to give you a T-score.

Normal: -1.0 or higher
Osteopenia (Low Bone Mass): Between -1.0 and -2.5
Osteoporosis: -2.5 or lower

(Note: Premenopausal women and younger men generally require Z-scores, which compare bones to people of the same age, and clinical context to establish a diagnosis).

Crucial Warning: For those on glucocorticoids (steroids) or aromatase inhibitors, these T-score numbers can be misleading ^[1]^[3]. Steroids damage the microscopic “scaffolding” inside your bones, meaning a glucocorticoid-treated person’s T-score carries a higher fracture risk than the same T-score in someone not taking steroids ^[4]^[5].

Adjunct Imaging: VFA and TBS

To get a complete view of your bone health, your care team may use these two additional tools, though they are not mandatory for every single patient:

Vertebral Fracture Assessment (VFA): This is a low-dose X-ray often taken at the same time as your DXA. It looks specifically at the shape of your spinal bones (vertebrae) to find “silent” fractures ^[6]. One study in a high-risk cohort found that over 40% of patients on certain bone-toxic meds had a spinal fracture despite having “normal” or “osteopenic” density on their DXA scan ^[3]. VFA is indicated when clinical factors like height loss or steroid exposure suggest a silent fracture might be present.
Trabecular Bone Score (TBS): This is an optional software tool that analyzes the “texture” of your DXA image. It provides a score that reflects the strength of your bone’s internal architecture ^[4]. While it is artifact-sensitive and not always available, if your density is “okay” but your TBS is “low,” it can help doctors realize your risk of fracture is higher than density alone would suggest ^[7]^[8].

Calculating Your Risk: The Adjusted FRAX

The FRAX (Fracture Risk Assessment Tool) is a calculator doctors use to predict your 10-year risk of a major fracture ^[9]. However, for patients on high-risk meds, the standard calculation must be adjusted:

The Steroid Adjustment: If you take more than 7.5 mg of prednisone daily, your 10-year risk of a hip fracture should be increased by about 20%, and your risk of a major osteoporotic fracture by about 15%, because the standard tool often underestimates steroid-related risk ^[9]^[10].
Limitations for Cancer Therapies: FRAX is not as well-adapted for aromatase inhibitors (AIs) or androgen deprivation therapy (ADT). Doctors often use distinct clinical factors to decide when to start treatment for patients on these medications ^[11]^[12].

Recommended Screening Timelines

Based on 2022 American College of Rheumatology (ACR) and oncology guidelines, screening timelines are typically individualized as follows:

Medication Type	Initial Screening	Follow-up Frequency
Glucocorticoids (Prednisone ≥2.5mg)	As soon as possible after starting ^[13]	Repeat DXA is often 12–24 months while on treatment ^[14]
Aromatase Inhibitors (AI)	Baseline (before or at start) ^[15]	Every 12–24 months ^[11]
Androgen Deprivation (ADT)	Baseline (before or at start) ^[16]	Every 12–24 months ^[16]
PPIs, SSRIs, Antiepileptics	Based on age/other risk factors	Discuss with your doctor if on long-term ^[17]

The Completeness Checklist

A thorough bone health report should not just be a single T-score. Ensure your assessment includes:

[ ] Clinical Fracture History: Documentation of any past broken bones.
[ ] BMD T-scores/Z-scores: For the lumbar spine, total hip, and femoral neck.
[ ] Vertebral Fracture Assessment (VFA): If indicated by height loss or risk factors, to rule out silent spinal fractures ^[15].
[ ] FRAX Score: Adjusted for your specific steroid dose (when age appropriate) ^[9].
[ ] Laboratory Work: Tests for Vitamin D, Calcium, and Kidney Function (creatinine) ^[16].
[ ] Trabecular Bone Score (TBS): If available, to assess bone quality ^[8].

Common questions in this guide

Can I have a high fracture risk if my DXA scan shows only osteopenia?

Yes. Glucocorticoids and some other medicines can weaken the internal structure of bone, so a person may have a significant fracture risk even with a normal or osteopenic DXA result. Your clinician may combine your medication and fracture history with tools such as VFA, TBS, and adjusted FRAX.

What do T-scores and Z-scores mean in drug-induced osteoporosis?

For postmenopausal women and men age 50 or older, a T-score compares bone density with that of a healthy young adult; a score of -2.5 or lower is in the osteoporosis range. Premenopausal women and younger men generally need a Z-score, which compares density with people of the same age, plus clinical context. Medication exposure can make the same score more concerning.

When should I have a DXA scan if I take prednisone or another bone-affecting medicine?

People taking prednisone or another glucocorticoid at a dose of at least 2.5 mg daily generally should have a bone-health assessment as soon as possible after treatment begins. Follow-up DXA is often repeated after 12–24 months while treatment continues. People starting aromatase inhibitors or androgen deprivation therapy commonly have a baseline scan and repeat testing every 12–24 months, but timing should be individualized.

What are VFA and TBS used for?

VFA is a low-dose X-ray that looks for vertebral fractures that may not have caused obvious symptoms, especially when there is height loss or steroid exposure. TBS is software that analyzes the texture of a DXA image to estimate the strength of the bone’s internal structure. Neither test is needed for every patient, and TBS availability varies.

How is FRAX adjusted for people taking steroids?

FRAX estimates the 10-year risk of a major osteoporotic fracture and hip fracture. When prednisone use is above 7.5 mg daily, clinicians may increase the calculated hip-fracture risk by about 20% and major-fracture risk by about 15% because standard FRAX can underestimate steroid-related risk. FRAX is less well adapted to aromatase inhibitors and androgen deprivation therapy, so other clinical factors may guide decisions.

What should a complete medication-related osteoporosis evaluation include?

A complete evaluation may include your history of fractures, DXA T-scores or Z-scores for the spine and hips, and blood tests for vitamin D, calcium, and kidney function. Depending on your risk, it may also include VFA, TBS, and a FRAX calculation adjusted for steroid dose. Ask your clinician how your medications and scan results change your fracture risk.

Get notified when new evidence is published on drug-induced osteoporosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (17)

1
Understanding and Managing Corticosteroid-Induced Osteoporosis.
Kobza AO, Herman D, Papaioannou A, et al.
Open access rheumatology : research and reviews 2021; (13()):177-190 doi:10.2147/OARRR.S282606.
PMID: 34239333
2
Treatment options for glucocorticoid-induced osteoporosis.
Chiodini I, Merlotti D, Falchetti A, Gennari L
Expert opinion on pharmacotherapy 2020; (21(6)):721-732 doi:10.1080/14656566.2020.1721467.
PMID: 32004105
3
High prevalence of vertebral fractures in seizure patients with normal bone density receiving chronic anti-epileptic drugs.
Dussault PM, McCarthy D, Davis SA, et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2021; (32(10)):2051-2059 doi:10.1007/s00198-021-05926-2.
PMID: 33822290
4
Bone status in glucocorticoid-treated men and women.
Leib ES, Winzenrieth R
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2016; (27(1)):39-48 doi:10.1007/s00198-015-3211-1.
PMID: 26252975
5
Prevention and treatment of glucocorticoid-induced osteoporosis in adults: recommendations from the European Calcified Tissue Society.
Paccou J, Yavropoulou MP, Naciu AM, et al.
European journal of endocrinology 2024; (191(6)):G1-G17 doi:10.1093/ejendo/lvae146.
PMID: 39556468
6
Making VFA Part of Standard Clinical DXA Assessment for Osteoporosis Care: Recommendations From the International Working Group on DXA Best Practices.
Lems WF, Ward KA, Lewiecki EM, et al.
Mayo Clinic proceedings 2025; (100(12)):2186-2205 doi:10.1016/j.mayocp.2025.08.005.
PMID: 41338753
7
Prediction of Incident Major Osteoporotic and Hip Fractures by Trabecular Bone Score (TBS) and Prevalent Radiographic Vertebral Fracture in Older Men.
Schousboe JT, Vo T, Taylor BC, et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2016; (31(3)):690-7 doi:10.1002/jbmr.2713.
PMID: 26378772
8
The Trabecular Bone Score (TBS) Complements DXA and the FRAX as a Fracture Risk Assessment Tool in Routine Clinical Practice.
Hans D, Šteňová E, Lamy O
Current osteoporosis reports 2017; (15(6)):521-531 doi:10.1007/s11914-017-0410-z.
PMID: 28988401
9
Fracture risk assessment by the FRAX model.
McCloskey EV, Harvey NC, Johansson H, et al.
Climacteric : the journal of the International Menopause Society 2022; (25(1)):22-28 doi:10.1080/13697137.2021.1945027.
PMID: 34319212
10
Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis.
Chiodini I, Falchetti A, Merlotti D, et al.
Expert review of endocrinology & metabolism 2020; (15(4)):283-298 doi:10.1080/17446651.2020.1772051.
PMID: 32584619
11
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.
Hadji P, Aapro MS, Body JJ, et al.
Journal of bone oncology 2017; (7()):1-12 doi:10.1016/j.jbo.2017.03.001.
PMID: 28413771
12
Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR.
Fukumoto S, Soen S, Taguchi T, et al.
Journal of bone and mineral metabolism 2020; (38(2)):141-144 doi:10.1007/s00774-020-01087-0.
PMID: 32020289
13
2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
Humphrey MB, Russell L, Danila MI, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2023; (75(12)):2088-2102 doi:10.1002/art.42646.
PMID: 37845798
14
Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy.
Diana A, Carlino F, Giunta EF, et al.
Current treatment options in oncology 2021; (22(5)):45 doi:10.1007/s11864-021-00835-2.
PMID: 33864145
15
Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer.
Waqas K, Lima Ferreira J, Tsourdi E, et al.
Journal of bone oncology 2021; (28()):100355 doi:10.1016/j.jbo.2021.100355.
PMID: 33948427
16
Bone health in patients with cancer: a SEOM-SEIOMM consensus review of risk factors, assessment strategies, and management approaches.
Beato-Zambrano C, Nogues X, Ramírez-Merino N, et al.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2026; (28(8)):3059-3074 doi:10.1007/s12094-026-04256-1.
PMID: 41703396
17
Increased Risk of Fractures and Use of Proton Pump Inhibitors in Menopausal Women: A Systematic Review and Meta-Analysis.
da Maia TF, de Camargo BG, Pereira ME, et al.
International journal of environmental research and public health 2022; (19(20)) doi:10.3390/ijerph192013501.
PMID: 36294082

This page explains diagnostic and screening tools for drug-induced osteoporosis for informational purposes only and does not constitute medical advice. Your clinician should interpret your DXA, fracture-risk results, and medication history in context.

Guide Contents